HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid To Launch With Risk Management Plan; Restrictions Could Be Lifted

Executive Summary

Celgene's Revlimid will launch under the risk management plan RevAssist to minimize fetal exposure, but the firm may lift the program if ongoing studies demonstrate there is no risk of teratogenicity
Advertisement

Related Content

Revlimid Cleared For Multiple Myeloma; Celgene Focuses On Thrombotic Risk
Revlimid Cleared For Multiple Myeloma; Celgene Focuses On Thrombotic Risk
FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec
FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
Celgene Revlimid Post-Market Phase III Study To Explore Lower Dose
Celgene Revlimid Post-Market Phase III Study To Explore Lower Dose
Advertisement
UsernamePublicRestriction

Register

PS046719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel